3 Promising Penny Stocks With Market Caps Over $100M

Over the last 7 days, the U.S. market has dropped 1.5%, but it has risen by 13% over the past year with earnings forecasted to grow annually by 17%. For investors willing to explore beyond well-known stocks, penny stocks—often representing smaller or newer companies—can offer intriguing opportunities despite their somewhat outdated reputation. This article explores three such penny stocks that stand out for their potential and financial resilience amidst current market conditions.

We'll examine a selection from our screener results.

LifeMD (LFMD)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: LifeMD, Inc. is a direct-to-patient telehealth company offering virtual medical care and pharmacy services in the United States, with a market cap of $147.01 million.

Operations: The company generates revenue from its telehealth segment, amounting to $191.59 million.

Market Cap: $147.01M

LifeMD, Inc. operates in the telehealth sector with a market cap of US$147.01 million and generates revenue from its telehealth segment amounting to US$191.59 million. Despite being unprofitable with a negative return on equity, it has reduced losses over the past five years at an annual rate of 31.7%. The company remains debt-free but faces challenges with short-term liabilities exceeding short-term assets by US$4.5 million and having less than one year of cash runway if historical free cash flow growth continues. Recent partnerships, such as co-marketing agreements for testosterone therapy programs, aim to bolster revenue streams amidst lowered earnings guidance for 2026.

• Take a closer look at LifeMD's potential here in our financial health report.
• Understand LifeMD's earnings outlook by examining our growth report.

OmniAb (OABI)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: OmniAb, Inc. is a biotechnology company that licenses discovery research technology to pharmaceutical and biotech companies, as well as academic institutions, to aid in the discovery of therapeutics across the United States, Europe, Japan, China, and Canada; it has a market cap of approximately $591.74 million.

Operations: The company's revenue is derived entirely from its Medical Labs & Research segment, totaling $38.46 million.

Market Cap: $591.74M

OmniAb, Inc., a biotechnology firm with a market cap of approximately US$591.74 million, has shown significant revenue growth, reporting US$13.42 million for Q2 2026 compared to US$3.9 million the previous year. Despite being unprofitable and having increased losses over the past five years, it remains debt-free with sufficient cash runway exceeding one year based on current free cash flow. Recent strategic collaborations, such as those with Eli Lilly and VERAXA Biotech AG, highlight its potential for future milestone payments up to US$370 million and expanded technological applications in therapeutic discovery despite recent index exclusions.

• Dive into the specifics of OmniAb here with our thorough balance sheet health report.
• Examine OmniAb's earnings growth report to understand how analysts expect it to perform.

Cytek Biosciences (CTKB)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Cytek Biosciences, Inc. is a company specializing in cell analysis solutions that support scientific progress in biomedical research and clinical applications, with a market cap of approximately $599.22 million.

Operations: The company generates revenue primarily from its Scientific & Technical Instruments segment, which amounted to $206.71 million.

Market Cap: $599.22M

Cytek Biosciences, Inc., with a market cap of US$599.22 million, is navigating the penny stock landscape through strategic collaborations and product innovations. Despite being unprofitable with increasing losses over five years, it maintains a strong cash position exceeding its debt and liabilities. Recent alliances, such as with Sysmex Europe SE to enhance clinical flow cytometry workflows across Europe, emphasize its commitment to expanding diagnostic solutions. The company has raised its revenue guidance for 2026 despite recent legal challenges and index exclusions. Cytek's advanced cell analysis technologies continue to gain traction in research applications globally.

• Unlock comprehensive insights into our analysis of Cytek Biosciences stock in this financial health report.
• Learn about Cytek Biosciences' future growth trajectory here.

Summing It All Up

• Explore the 318 names from our US Penny Stocks screener here.
• Want To Explore Some Alternatives? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com